- Knight Therapeutics (GUD) has now obtained approval for one of its treatments in Colombia
- The Montreal pharmaceutical company got the approval through its Colombian affiliate, Biotoscana
- The company’s oral drug Lenvima, is used as a treatment for a type of thyroid cancer as well as a type of carcinoma
- Knight has an exclusive license to commercialize Lenvima
- Knight Therapeutics is down 0.19 per cent, trading at $5.29 at 2:27 p.m. EST
Knight Therapeutics (GUD) has now obtained approval for one of its treatments in Colombia.
The Montreal pharmaceutical company received approval from Colombia’s national agency INVIMA through its Colombian affiliate, Biotoscana.
The company’s drug, Lenvima, is an orally-available multiple receptor tyrosine kinase inhibitor developed by Esai, for the treatment of radioiodine refractory differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Knight has an exclusive license from Eisai to commercialize Lenvima.
In 2020, there were approximately 5,304 new patients with thyroid cancer and 2,289 new patients with liver cancer in Colombia.
“We’re pleased to announce the approval of Lenvima in Colombia as it provides a new treatment option for radioiodine refractory differentiated thyroid cancer and unresectable hepatocellular carcinoma. We look forward to working with payors to ensure access to the product for all patients who can benefit from Lenvima,” said Knight Therapeutics President and Chief Executive Officer Samira Sakhia.
Lenvima has been approved for monotherapy as a treatment for thyroid cancer in over 75 countries including Japan, in Europe, China and in Asia, and in the United States for locally recurrent or metastatic, progressive, radioiodine-refractory differentiated thyroid cancer.
It has also been approved for monotherapy as a treatment for unresectable hepatocellular carcinoma in over 70 countries including Japan, in Europe, China and in Asia, and in the United States for first-line unresectable hepatocellular carcinoma.
Knight Therapeutics is down 0.19 per cent, trading at $5.29 at 2:27 p.m. EST.
